SIGLEC9

Across TCGA pan-cancer cohorts, SIGLEC9 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SIGLEC9 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SIGLEC9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SIGLEC9 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

GBM, LSCC, and LUAD are the cancer types where SIGLEC9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.634	0.812	.015	10	view →
LSCC	OS	Tertile	III,IV	1.000	0.537	.027	7	view →
LUAD	DFS	Median	All	0.526	0.720	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SIGLEC9–GBM (DFS)

Open the GBM breakdown →